Securities Class Actions Mount Against CIGL, FBRT, IBRX Over Alleged Fraud

Rosen Law Firm is actively recruiting lead plaintiffs in multiple securities class action lawsuits targeting Concorde International Group Ltd. ($CIGL), Franklin BSP Realty Trust, Inc. ($FBRT), and ImmunityBio, Inc. ($IBRX), with a critical May 20, 2026 deadline looming for investors seeking to participate in the litigation. The coordinated legal action alleges systematic violations of securities law, including fraudulent stock promotion schemes, materially misleading statements to investors, and undisclosed trading activities that may have artificially inflated share prices or concealed material information.

For investors holding shares in these companies during relevant periods, securing qualified legal counsel before the approaching deadline has become essential to protecting potential recovery rights. The cases represent a significant development in securities enforcement, highlighting ongoing concerns about disclosure practices and trading transparency across multiple market sectors.

The Allegations and Legal Framework

The securities class actions brought against these three companies center on serious allegations that strike at the heart of investor protection regulations:

• Fraudulent stock promotion schemes: Allegations suggest coordinated efforts to artificially promote securities without adequate disclosure of material risks or conflicts of interest
• Misleading statements to investors: Claims that companies made false or materially incomplete representations regarding business operations, financial condition, or market prospects
• Undisclosed trading activities: Suggestions of insider trading or other trading practices not properly disclosed to public shareholders

These allegations, if substantiated, would represent violations of the Securities Exchange Act and potentially state common law fraud statutes. The fact that Rosen Law Firm, a nationally recognized securities litigation practice, is coordinating representation across three separate entities suggests legal counsel has identified patterns or related conduct worth investigating at an institutional level.

The May 20, 2026 deadline represents the cutoff date for investors to apply to become lead plaintiffs in these actions. Lead plaintiff status carries significant importance—these designated investors will have greater input into litigation strategy, settlement negotiations, and distribution of any recovery. The deadline creates urgency for affected shareholders to evaluate their eligibility and potential claims.

Market Context and Investor Vulnerabilities

These class actions emerge within a broader environment of heightened scrutiny of securities disclosures and trading practices. The Securities and Exchange Commission (SEC) has substantially increased enforcement actions related to disclosure violations and promotional schemes, particularly following high-profile corporate failures and market manipulation cases.

Concorde International Group Ltd. ($CIGL), Franklin BSP Realty Trust ($FBRT), and ImmunityBio ($IBRX) operate across different sectors—international commerce, real estate investment trusts, and biopharmaceuticals respectively—yet face similar allegations regarding disclosure integrity. This cross-sector pattern suggests that problematic practices may be more endemic than isolated incidents.

The real estate investment trust sector, represented by $FBRT, has faced particular scrutiny in recent years regarding valuation methodologies, related-party transactions, and disclosure of conflicts of interest. Similarly, biopharmaceutical companies like $IBRX operate in environments where accurate disclosure of clinical trial results, regulatory pathways, and cash burn rates are critical to informed investment decisions.

Investors in smaller or less liquid publicly traded companies face particular vulnerability to promotional schemes and undisclosed trading manipulation, as these securities attract less analyst coverage and institutional oversight than large-cap equities. The involvement of Rosen Law Firm suggests sophisticated analysis identifying patterns consistent with securities fraud rather than isolated disclosure lapses.

Investor Implications and Recovery Considerations

For shareholders who purchased shares of $CIGL, $FBRT, or $IBRX during periods when these alleged violations occurred, several critical implications warrant attention:

Potential Recovery Rights: Securities class actions, when successful, can recover significant damages for affected investors. Historical settlements in securities fraud cases have returned hundreds of millions of dollars to injured shareholders, though recovery rates and timelines vary substantially based on case merits and defendant financial resources.

Timing and Procedural Requirements: The May 20, 2026 deadline is not merely a suggestion—missing this cutoff typically extinguishes an investor's right to participate in litigation and receive recovery distributions. Investors uncertain about their eligibility or holdings should consult legal counsel immediately to preserve rights.

Stock Price Impact: Securities fraud allegations frequently cause material stock price declines as market participants reassess company valuations in light of disclosure failures. Investors may experience both the impact of the alleged fraud itself (inflated valuations collapsing) and subsequent litigation-related volatility.

Comparative Liability Questions: The involvement of three separate companies raises important questions about whether these are truly independent issues or whether related parties, affiliates, or common service providers (such as promoters, transfer agents, or investment advisors) were involved across multiple entities. Such connections could expand potential liability.

Forward-Looking Considerations

These coordinated class actions underscore the continued importance of investor due diligence, particularly regarding securities offered by smaller public companies or those with complex corporate structures. Investors should scrutinize SEC filings, particularly Form 8-Ks (material events), Form 4s (insider trading), and detailed disclosures regarding related-party transactions and business relationships.

The approaching May 20, 2026 deadline creates immediate action items for affected shareholders. Those believing they may have claims should document their purchase and sale transactions, gather relevant account statements and confirmations, and consult experienced securities counsel to evaluate lead plaintiff eligibility and potential recovery prospects.

As these cases progress through litigation discovery phases, they will likely produce detailed revelations about disclosure practices, trading activities, and promotional methods within these companies. Such disclosure may have broader implications for regulatory enforcement priorities and investor protection standards across comparable market participants.